Pasireotide—a novel somatostatin receptor ligand after 20 years of use

Pasireotide, a novel multireceptor-targeted somatostatin receptor ligand (SRL) is characterized by a higher affinity to somatostatin receptor type 5 than type 2, unlike first-generation SRLs. Because of the broader binding profile, pasireotide has been suggested to have a greater clinical efficacy i...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolanowski, Marek, Kałużny, Marcin, Witek, Przemysław, Jawiarczyk-Przybyłowska, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156514/
https://www.ncbi.nlm.nih.gov/pubmed/35067849
http://dx.doi.org/10.1007/s11154-022-09710-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156514/
https://www.ncbi.nlm.nih.gov/pubmed/35067849
http://dx.doi.org/10.1007/s11154-022-09710-3

Ejemplares similares